Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1710-1713

  Sawada, Akihisa ^a   Sakata, Naoki ^a   Kishimoto, Tomoko ^b   Higuchi, Banryoku ^b   Koyama, Maho ^a   Kondo, Osamu ^a   Sato, Emiko ^a   Okamura, Takayuki ^a   Yasui, Masahiro ^a   Inoue, Masami ^a   Yoshioka, Akira ^b   Kawa, Keisei ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute lymphoblastic leukemia; Flow cytometry; Minimal residual disease; PCR; Pediatric; WT1

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; PREDNISOLONE; WT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHIMERA; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70249125755     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.016     Document Type: Article

References (9)

1. Cavé H., van der Werff Ten Bosch J., Suciu S., Guidal C., Waterkeyn C., Otten J., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 339 (1998) 591-598
2. van Dongen J.J., Seriu T., Panzer-Grümayer E.R., Biondi A., Pongers-Willemse M.J., Corral L., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352 (1998) 1731-1738
3. Coustan-Smith E., Sancho J., Hancock M.L., Boyett J.M., Behm F.G., Raimondi S.C., et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96 (2000) 2691-2696
4. Hara J. Acute lymphoblastic leukemia, JACLS protocol. Tsukimoto I. Treatment protocols for pediatric blood and cancer. Iyaku Journal (Osaka) (2003) 63-72 (in Japanese)
5. Smith M., Arthur D., Camitta B., Carroll A.J., Crist W., Gaynon P., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14 (1996) 18-24
6. Coustan-Smith E., Behm F.G., Sanchez J., Boyett J.M., Hancock M.L., Raimondi S.C., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351 (1998) 550-554
7. Robillard N., Cavé H., Méchinaud F., Guidal C., Garnache-Ottou F., Rohrlich P.S., et al. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica 90 (2005) 1516-1523
8. Madzo J., Zuna J., Muzíková K., Kalinová M., Krejcí O., Hrusák O., et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 97 (2003) 105-113
9. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178